Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail

This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.

Detalles Bibliográficos
Autores principales: van den Boom, Louisa, Stuecher, Theresa, Mader, Julia K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449226/
https://www.ncbi.nlm.nih.gov/pubmed/34567554
http://dx.doi.org/10.1002/ccr3.4811
_version_ 1784569386046062592
author van den Boom, Louisa
Stuecher, Theresa
Mader, Julia K.
author_facet van den Boom, Louisa
Stuecher, Theresa
Mader, Julia K.
author_sort van den Boom, Louisa
collection PubMed
description This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control.
format Online
Article
Text
id pubmed-8449226
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-84492262021-09-24 Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail van den Boom, Louisa Stuecher, Theresa Mader, Julia K. Clin Case Rep Case Report This case report demonstrates that using a non‐approved long‐acting GLP‐1‐RA (dulaglutide) in adolescents with T2D is possible and feasible under special circumstances when approved therapeutic options for the pediatric population fail to achieve adequate glycemic control. John Wiley and Sons Inc. 2021-09-18 /pmc/articles/PMC8449226/ /pubmed/34567554 http://dx.doi.org/10.1002/ccr3.4811 Text en © 2021 The Authors. Clinical Case Reports published by John Wiley & Sons Ltd. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ (https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Case Report
van den Boom, Louisa
Stuecher, Theresa
Mader, Julia K.
Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
title Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
title_full Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
title_fullStr Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
title_full_unstemmed Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
title_short Safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
title_sort safe use of a once‐a‐week glucagon‐like peptide‐1 receptor agonist in a 16‐year‐old girl with type 2 diabetes when approved therapy options fail
topic Case Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8449226/
https://www.ncbi.nlm.nih.gov/pubmed/34567554
http://dx.doi.org/10.1002/ccr3.4811
work_keys_str_mv AT vandenboomlouisa safeuseofaonceaweekglucagonlikepeptide1receptoragonistina16yearoldgirlwithtype2diabeteswhenapprovedtherapyoptionsfail
AT stuechertheresa safeuseofaonceaweekglucagonlikepeptide1receptoragonistina16yearoldgirlwithtype2diabeteswhenapprovedtherapyoptionsfail
AT maderjuliak safeuseofaonceaweekglucagonlikepeptide1receptoragonistina16yearoldgirlwithtype2diabeteswhenapprovedtherapyoptionsfail

Ejemplares similares